Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
To compare the clinical efficacy and safety of telitacicept versus traditional regimens in the treatment of recurrent IgA nephropathy after kidney transplantation.
This was a single-center retrospective cohort study. A total of 68 patients admitted to our hospital from September 2018 to September 2025 were enrolled and divided into the telitacicept treatment group (21 cases) and the conventional treatment group (47 cases) according to the therapeutic regimen. Measurement data were expressed as "mean ± standard deviation (x±s)". Paired t-test was used for intragroup comparison before and after treatment, and independent samples t-test was used for intergroup comparison. Count data were expressed as "cases (%)", and the χ² test was used for comparison. A P value < 0.05 was considered statistically significant.
1. Urine protein remission rate: At 6 months of treatment, in the telitacicept group, 9 cases (42.9%) achieved complete remission (24-hour urine protein < 0.3g), 10 cases (47.6%) achieved partial remission (≥50% reduction from baseline and > 0.3g), with an overall remission rate of 90.5%. In the conventional treatment group, 3 cases (6.4%) achieved complete remission, 11 cases (23.4%) achieved partial remission, with an overall remission rate of 29.8%. The overall remission rate of the telitacicept group was significantly higher than that of the conventional treatment group (χ²=21.367, P<0.001).
2. Renal function stability rate: At 6 months of treatment, the serum creatinine of all 21 patients in the telitacicept group met the "stable" standard (stability rate 100%). In the conventional treatment group, only 32 patients had stable serum creatinine (stability rate 68.1%), and 15 patients had a serum creatinine increase of ≥5% from baseline (3 of which were close to the "deterioration" standard). The renal function stability rate of the telitacicept group was significantly higher than that of the conventional treatment group (χ²=8.724, P=0.003).
3. Only 2 cases (9.5%) in the telitacicept group had mild injection site pruritus, which resolved spontaneously within 1 week without drug withdrawal. Adverse reactions occurred in 15 cases (31.9%) in the conventional treatment group, including leukopenia in 5 cases (10.6%), gastrointestinal discomfort in 4 cases (8.5%), elevated blood glucose in 3 cases (6.4%), and osteoporosis in 2 cases (4.3%). Three cases suspended cyclophosphamide treatment due to leukopenia. The incidence of adverse reactions in the telitacicept group was significantly lower than that in the conventional treatment group (χ²=4.872, P=0.027).
For patients with recurrent IgA nephropathy after kidney transplantation, telitacicept treatment can achieve a significant and sustained reduction in urine protein. Telitacicept can effectively maintain stable renal function and has a significant safety advantage. Combining the advantages of efficacy and safety, telitacicept can be used as the preferred treatment option for patients with recurrent IgA nephropathy after kidney transplantation, especially for those with poor efficacy or poor tolerance to traditional immunosuppressants. Future multi-center prospective randomized controlled studies are needed to further verify its long-term efficacy and safety.
